Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesisD Ménaché, Gilbert White, Jeanne M. Lusher et al.|British Journal of Haematology|1996Cited by 57
Variability of In Vivo Recovery of Factor IX after Infusion of Monoclonal Antibody Purified Factor IX Concentrates in Patients with Hemophilia BGilbert White, Amy D. Shapiro, Elizabeth Kurczynski et al.|Thrombosis and Haemostasis|1995Cited by 27
Low risk of viral infection after administration of vapor‐heated factor VII concentrate or factor IX complex in first‐time recipients of blood components. International Factor Safety Study GroupAmy D. Shapiro, Takaya Abe, Louis M. Aledort et al.|Transfusion|1995Cited by 19
Safety of high doses of a monoclonal antibody‐purified factor IX concentrateIndira Warrier, Garrett E. Bergman, Carol K. Kasper et al.|American Journal of Hematology|1995Cited by 6